» Articles » PMID: 32397563

Exposure of to Environmental Stress and Clinically Used Antibiotics Reveals Common Proteome Response Among Pathogenic Mycobacteria

Overview
Journal Microorganisms
Specialty Microbiology
Date 2020 May 14
PMID 32397563
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

subsp. (MAB) is a clinically important nontuberculous mycobacterium (NTM) causing pulmonary infection in patients such as cystic fibrosis and bronchiectasis. MAB is naturally resistant to the majority of available antibiotics. In attempts to identify the fundamental response of MAB to aerobic, anaerobic, and biofilm conditions (as it is encountered in patients) and during exposure to antibiotics, we studied bacterial proteome using tandem mass tag mass spectrometry sequencing. Numerous de novo synthesized proteins belonging to diverse metabolic pathways were found in anaerobic and biofilm conditions, including glycolysis/gluconeogenesis, tricarboxylic acid (TCA) cycle, oxidative phosphorylation, nitrogen metabolism, and glyoxylate and dicarboxylate metabolism. Upon exposure to amikacin and linezolid under stress environments, MAB displayed metabolic enrichment for glycerophospholipid metabolism and oxidative phosphorylation. By comparing proteomes of two significant NTMs, MAB and subsp. , we found highly synthesized shared enzymes of oxidative phosphorylation, TCA cycle, glycolysis/gluconeogenesis, glyoxylate/dicarboxylate, nitrogen metabolism, peptidoglycan biosynthesis, and glycerophospholipid/glycerolipid metabolism. The activation of peptidoglycan and fatty acid biosynthesis pathways indicates the attempt of bacteria to modify the cell wall, influencing the susceptibility to antibiotics. This study establishes global changes in the synthesis of enzymes promoting the metabolic shift and enhancing the pathogen resistance to antibiotics within different environments.

Citing Articles

Discovery of Biofilm-Inhibiting Compounds to Enhance Antibiotic Effectiveness Against Infections.

Dzalamidze E, Gorzynski M, Vande Voorde R, Nelson D, Danelishvili L Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006039 PMC: 11859778. DOI: 10.3390/ph18020225.


Exposure of Mycobacteriodes abscessus clones to mucin affects bacterial phenotype.

Leestemaker-Palmer A, Ong T, Bermudez L Sci Rep. 2025; 15(1):393.

PMID: 39747334 PMC: 11697318. DOI: 10.1038/s41598-024-84451-8.


A laboratory perspective on biofilm culture, characterization and drug activity testing.

Meliefste H, Mudde S, Ammerman N, de Steenwinkel J, Bax H Front Microbiol. 2024; 15:1392606.

PMID: 38690364 PMC: 11058659. DOI: 10.3389/fmicb.2024.1392606.


Rapid Mycobacterium abscessus antimicrobial susceptibility testing based on antibiotic treatment response mapping via Raman Microspectroscopy.

Ren W, Mao Y, Li S, Gao B, Fu X, Liu X Ann Clin Microbiol Antimicrob. 2023; 22(1):94.

PMID: 37904155 PMC: 10617219. DOI: 10.1186/s12941-023-00644-5.


Understanding the Phage-Host Interaction Mechanism toward Improving the Efficacy of Current Antibiotics in .

Gorzynski M, De Ville K, Week T, Jaramillo T, Danelishvili L Biomedicines. 2023; 11(5).

PMID: 37239050 PMC: 10216323. DOI: 10.3390/biomedicines11051379.


References
1.
Xiao Y, Hsiao T, Suresh U, Chen H, Wu X, Wolf S . A novel significance score for gene selection and ranking. Bioinformatics. 2012; 30(6):801-7. PMC: 3957066. DOI: 10.1093/bioinformatics/btr671. View

2.
Wu M, Aziz D, Dartois V, Dick T . NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018; 23(8):1502-1519. PMC: 6078814. DOI: 10.1016/j.drudis.2018.04.001. View

3.
Wang Y, Yang F, Gritsenko M, Wang Y, Clauss T, Liu T . Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics. 2011; 11(10):2019-26. PMC: 3120047. DOI: 10.1002/pmic.201000722. View

4.
Stout J, Koh W, Yew W . Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 2016; 45:123-34. DOI: 10.1016/j.ijid.2016.03.006. View

5.
Wayne L, Hayes L . An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996; 64(6):2062-9. PMC: 174037. DOI: 10.1128/iai.64.6.2062-2069.1996. View